The rapid test paradox: When fewer cases detected lead to more cases treated: A decision analysis of tests for Chlamydia trachomatis

Sexually Transmitted Diseases

Volumn 26, Issue 4, 1999, Pages 232-240

  Gift, Thomas L ^a   Pate, Mitchell S ^b   Hook III, Edward W ^b   Kassler, William J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE FINDING; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; INFECTION CONTROL; POLYMERASE CHAIN REACTION; RELIABILITY; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE;

EID: 0032966108     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199904000-00010     Document Type: Article

References (43)

1. The Neglected Health and Economic Impact of STDs. In: Eng TR, Butler WT, eds. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington: National Academy Press, 1997:28-68.
2. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Trans Dis 1995; 22:274-280.
3. Marrazzo JM, Celum CL, Hillis SD, Fine D, DeLisle S, Handsfield HH. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Sex Transm Dis 1997; 24:131-141.
4. Westrom L, Joesoef R, Reynolds G, Hadgu A. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19:185-192.
5. Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880-892.
6. Fish AN, Fairweather DV, Oriel JD, Ridgeway GL. Chlamydia trachomatis infection in a gynecology clinic population: identification of high-risk groups and the value of contact tracing. Eur J Obstet Gynecol Reprod Biol 1989; 31:67-74.
7. Stamm WE, Holmes KK. Chlamydia trachomatis infections of the adult. In: Holmes KK, Mardh P-A, Sparling PF, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1990:181-193.
8. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydia infection. N Engl J Med 1996; 334:1362-1366.
9. Black CM. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997; 10:160-184.
10. Hook EW III, Spitters C, Reichart CA, Neumann TM, Quinn TC. Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening. JAMA 1994; 272:867-870.
11. Foglia G, Goldberg M, St. Louis ME. Assurance of and duration to treatment after screening for Chlamydia trachomatis (Ct) infections [Abstract]. International Congress of Sexually Transmitted Diseases, Seville, Spain, October 19-22, 1997. P732.
12. Schwebke JR, Sadler R, Sutton JM, Hook EW III. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis 1997; 24:181-184.
13. Aral SO, Holmes KK, Padian NS, Cates W Jr. Overview: individual and population approaches to the epidemiology and prevention of sexually transmitted diseases and human immunodeficiency virus infection. J Infect Dis 1997; 174:S127-S133.
14. Kassler WJ, Dillon BA, Haley C, Jones WK, Goldman A. On-site, rapid HIV testing with same-day results and counseling. AIDS 1997; 11:1045-1051.
15. Patton DL, Askienazy-Elbhar M, Henry-Suchet J, et al. Detection of Chlamydia trachomatis in fallopian tube tissue in women with postinfectious tubal infertility. Am J Obstet Gynecol 1994; 171:95-101.
16. Cates W Jr, Joesoef MR, Goldman MB. Atypical pelvic inflammatory disease: can we identify the clinical predators? Am J Obstet Gynecol 1993; 169:341-346.
17. Washington AE, Johnson RE, Sanders LL Jr. Chlamydia trachomatis infections in the United States: what are they costing us? JAMA 1987; 257:2070-2072.
18. Washington AE, Arno PS, Brooks MA. The economic cost of pelvic inflammatory disease. JAMA 1986; 255:1735-1738.
19. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease trends and projections. JAMA 1991; 266: 2565-2569.
20. Centers for Disease Control and Prevention. Recommendations for the prevention and management of Chlamydia trachomatis infections. MMWR Morbid Mortal Wkly Rep 1993; 42:1-39.
21. Suchland KL, Counts JM, Stamm WE. Laboratory methods for detection of Chlamydia trachomatis: survey of laboratories in Washington State. J Clin Microbiol 1997; 35:3210-3214.
22. Pate MS, Dixon PB, Hardy K, Crosby M, Hook EW III. Evaluation of the Biostar Chlamydia OIA Assay in women attending a sexually transmitted disease clinic. J Clin Microbiol 1998; 36:2183-2186.
23. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 1996 Supplement. U.S. Department of Health & Human Services, Atlanta, GA, 1998.
24. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992; 327:921-925.
25. Hillis SD, Coles FB, Litchfield B, et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. Sex Transm Dis 1998; 25:5-11.
26. Howell MR, Quinn TC, Brathwaite W, Gaydos CA. Screening women for Chlamydia trachomatis in family planning clinics. Sex Transm Dis 1998; 25:108-117.
27. Dean D, Ferrero D, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection. J Clin Microbiol 1998; 36:94-99.
28. Steece R. National Pricing of Chlamydia Reagents. Association of State and Territorial Public Health Laboratory Directors, 1997 (Memo).
29. Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. Ann Intern Med 1998; 128:277-284.
30. Handsfield HH, Stamm WE. Treating chlamydial infection: compliance versus cost. Sex Transm Dis 1998; 25:12-13.
31. Rees E. The treatment of pelvic inflammatory disease. Am J Obstet Gynecol 1980; 138:1042-1047.
32. Stamm WE, Guinan ME, Johnson C, Starcher T, Holmes KK, McCormack WM. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984; 310:545-549.
33. Rein D, Kassler WJ, Tao G, Rabiee L. Decreasing, but still substantial: the direct medical cost of pelvic inflammatory disease and its sequelae, chronic pelvic pain, ectopic pregnancy, and infertility [Abstract]. National STD Prevention Congress, Dallas, Texas, December 6-9, 1998. A1.
34. Stinnett AA, Mullahy J. The negative side of cost-effectiveness analysis [Letter]. JAMA 1997; 277:1931-1932.
35. Bachmann LH, Richey C, Waites K, Schwebke JR, Hook EW III. Patterns of Chlamydia trachomatis testing and follow-up at a university hospital medical center [Abstract]. International Congress of Sexually Transmitted Diseases, Seville, Spain, October 19-22, 1997. P793.
36. Oh MK, Smith MR, O'Cain M, Kilmer D, Johnson J, Hook EW III. Urine based screening of adolescents in detention to guide treatment for gonococcal and chlamydial infections: translating research into intervention. Arch Pediatr Adolesc Med 1998; 152:52-56.
37. Mertz KJ, Levine WC, Mosure DJ, Berman SM, Dorian KJ, Hadgu A. Screening women for gonorrhea: demographic screening criteria for general clinical use. Am J Public Health 1997; 87:1535-1538.
38. Miller WC. Screening for chlamydial infection: a model program based on prevalence. Sex Transm Dis 1998; 25:201-210.
39. Mayaud P, Grosskurth H, Changalucha J, et al. Risk assessment and other screening options for gonorrhoeae and chlamydial infections in women attending rural Tanzanian antenatal clinics. Bull World Health Organ 1995; 73:621-630.
40. Sellors JW, Pickard L, Gafni A, et al. Effectiveness and efficiency of selective vs. universal screening for chlamydial infection in sexually active young women. Arch Intern Med 1992; 152:1837-1844.
41. Addiss DG, Vaughn ML, Ludka D, Pfister J, Davis JP. Decreased prevalence of Chlamydia trachomatis infection associated with a selective screening program in family planning clinics in Wisconsin. Sex Transm Dis 1993; 20:28-35.
42. Bureau of Labor Statistics. Average hourly and weekly earnings of production or nonsupervisory workers on private nonfarm payrolls by major industry, seasonally adjusted. Employment and Earnings, Table B 11, 1998.
43. Graney DO, Vontver LA. Anatomy and physical examination of the female genital tract. In: Holmes KK, Mardh P-A, Sparling PF, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1990: 105-115.